{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bites-human-animal/prescribing-information/co-amoxiclav/","result":{"pageContext":{"chapter":{"id":"0e041b11-cf29-519b-99be-1751ece6b17e","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav","depth":2,"htmlHeader":"<!-- begin field 0692b319-1404-49e2-b06d-a877009b19ef --><h2>Co-amoxiclav</h2><!-- end field 0692b319-1404-49e2-b06d-a877009b19ef -->","summary":"","htmlStringContent":"<!-- begin item c4d00714-19a5-4c2d-8286-a877009b175e --><!-- end item c4d00714-19a5-4c2d-8286-a877009b175e -->","topic":{"id":"66885481-1c78-50d7-bd40-cee6daf3a22b","topicId":"1f9ba5f4-d4ca-402b-857f-1ef0227e6eaa","topicName":"Bites - human and animal","slug":"bites-human-animal","lastRevised":"Last revised in October 2020","chapters":[{"id":"4d7c4615-e565-58f7-ab3f-9af67d5fa066","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d9aea4af-b77b-548e-a62d-b1b69d689e70","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b16f539f-9832-520a-b08e-b9870416e2ef","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"814b9650-9309-581c-ad8b-77bd0f59d573","slug":"changes","fullItemName":"Changes"},{"id":"451e8923-57cf-55b9-88b6-7767cf1870b3","slug":"update","fullItemName":"Update"}]},{"id":"4f4d63cd-fedc-53a6-9963-001d4f253f2c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8bb57dc0-b6ce-5ebb-a31d-25b2d527ed6c","slug":"goals","fullItemName":"Goals"},{"id":"51f172a3-e955-5bda-98c3-61a0bd719f16","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"150a707d-3a0a-5115-b633-9ab844daab23","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"77f07ad2-c9ad-5bc2-9b81-5c305f9e8ca3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"51c4f343-6ac9-549d-a068-43084108f8c5","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"909ff9e5-d816-5a1a-a545-0b5d010352f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"601e2fbe-0e18-597e-9476-633c9f4ef7b3","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a5c3cdd6-9531-5a6c-b1bc-a6e8d12b2307","slug":"definition","fullItemName":"Definition"},{"id":"2158dea0-437f-5805-9e65-e1c277e52475","slug":"characteristics-of-different-types-of-bites","fullItemName":"Characteristics of different types of bites"},{"id":"dcc5a332-7954-5ea2-88e1-7093a2c27960","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d2e33eaa-035d-54f9-b1e6-ee9d3c605297","slug":"complications","fullItemName":"Complications"},{"id":"f9c4fd96-ca8a-53ba-bb96-fe24ea11c8be","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"27cd943b-33a7-5304-8c4f-0f2da1c77fb9","fullItemName":"Management","slug":"management","subChapters":[{"id":"4a38ec65-3aac-5dff-b0e6-ce328b564e2d","slug":"managing-a-human-bite","fullItemName":"Scenario: Managing a human bite"},{"id":"3998b5bd-33dc-52ed-848d-b1c3b6d01573","slug":"managing-a-cat-or-dog-bite","fullItemName":"Scenario: Managing a cat or dog bite"}]},{"id":"cc488aaa-0221-5616-92c9-e9b9a28c206a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a0c8184c-9c4d-5943-9d34-6471f2fe8744","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"0e041b11-cf29-519b-99be-1751ece6b17e","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"7398d7dd-8a7d-5695-b963-bba32a0445a8","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"696d5b30-ff2f-5b72-875c-03cf5db390c0","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"6410092b-90ae-58a9-8065-103199eca1cb","slug":"paracetamol-ibuprofen","fullItemName":"Paracetamol and ibuprofen"}]},{"id":"703fd48e-b059-5fac-8aef-986c90ceca15","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"869edd83-cb34-55d6-9d47-6931a23adf4e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8e9f1883-896e-54dd-8156-ae8a2aa744d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3edab9d3-1d3a-5e9d-b8df-83d2ffc14bf0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e969da1-bdae-5ba7-9471-72cff35d2dac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e8d0ba91-234c-5494-a990-bbe559b68c05","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e2e4ab4-ad2f-5ad9-a9c6-3d59693be83c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bdc0f3ee-0644-5a81-b04b-3f1ae3e4310b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"cc488aaa-0221-5616-92c9-e9b9a28c206a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"82552520-86d4-5168-8818-80cb0db63f1e","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field 55834941-44e7-4379-96e4-a877009c6fdc --><h3>What dosage of co-amoxiclav should I prescribe?</h3><!-- end field 55834941-44e7-4379-96e4-a877009c6fdc -->","summary":"","htmlStringContent":"<!-- begin item 0bc086e2-846a-47fa-b2f6-a877009c6d3a --><!-- begin field 6a1c98f6-79a6-466f-bfb0-a877009c6fdc --><ul><li>For treatment of an infected bite wound, the dosage of oral co-amoxiclav is:<ul><li>Adult: 250/125 mg or 500/125 mg 3 times a day for 5 days</li><li>Child 1–11 months: 0.25 mL/kg of 125/31 suspension three times a day for 5 days. </li><li>Child 1–5 years: 0.25 mL/kg of 125/31 suspension three times a day, or 5 mL three times a day, for 5 days. </li><li>Child 6–11 years: 0.15 mL/kg of 250/62 suspension three times a day, or 5 mL three times a day, for 5 days. </li><li>Child 12–17 years: 250/125 mg (tablet) or 500/125 mg 3 times a day for 5 days. </li></ul></li><li>For prophylaxis of a bite the dosage is as described above but prescribed for 3 days in both adults and children. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">PHE, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">NICE, 2020</a>]</p><!-- end field 6a1c98f6-79a6-466f-bfb0-a877009c6fdc --><!-- end item 0bc086e2-846a-47fa-b2f6-a877009c6d3a -->","subChapters":[]},{"id":"57c28082-f4c9-5b35-aca2-e039c42269c0","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8d90bd82-4162-475e-ac09-a877009c98ce --><h3>What are the contraindications and cautions when prescribing co-amoxiclav?</h3><!-- end field 8d90bd82-4162-475e-ac09-a877009c98ce -->","summary":"","htmlStringContent":"<!-- begin item 8ae09428-cdc2-4345-b2e2-a877009c9618 --><!-- begin field 473fef82-f433-45f8-9045-a877009c98ce --><ul><li><strong>Do not prescribe co-amoxiclav in people with:</strong><ul><li>A <em>true </em>penicillin allergy — allergic reactions to penicillins occur in 1–10% of exposed individuals; anaphylactic reactions occur in fewer than 0.05% of treated patients.</li><li>Gastrointestinal adverse effects alone (for example nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li><li>A history of co-amoxiclav- or penicillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe co-amoxiclav with caution in people with:</strong><ul><li>A hypersensitivity to cephalosporins — there is some evidence of partial cross-allergenicity. </li><li>Hepatic impairment – monitor closely.</li><li>Chronic kidney disease (CKD) — reduce the dose if the estimated glomerular filtration rate (eGFR) is 30 mL/minute/1.73 m<sup>2</sup> or less.</li><li>Acute lymphocytic leukaemia, chronic lymphocytic leukaemia, cytomegalovirus infection, glandular fever — increased risk of erythematous rashes.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>]</p><!-- end field 473fef82-f433-45f8-9045-a877009c98ce --><!-- end item 8ae09428-cdc2-4345-b2e2-a877009c9618 -->","subChapters":[]},{"id":"1e6fa081-ea5b-5cdf-bb51-0c3839475f57","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 43791c16-17ce-4f45-8399-a877009cbbb4 --><h3>What are the adverse effects of co-amoxiclav?</h3><!-- end field 43791c16-17ce-4f45-8399-a877009cbbb4 -->","summary":"","htmlStringContent":"<!-- begin item 45c70add-38a7-4c30-9d49-a877009cb8dd --><!-- begin field 7297f544-d007-4654-97a0-a877009cbbb4 --><ul><li><strong>Gastrointestinal </strong>— nausea and vomiting (common), vomiting (very common).<ul><li><strong>Very rarely: </strong>antibiotic-associated colitis.</li></ul></li><li><strong>Nervous system</strong> — headache, dizziness (uncommon).</li><li><strong>Skin</strong> — skin rash, urticaria and pruritus (uncommon).<ul><li><strong>Very rarely:</strong> erythema multiforme, Stevens–Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis, and acute generalized exanthematous pustulosis.</li></ul></li><li><strong>Other rare, or very rare adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Hepatitis, cholestatic jaundice.</li><li>Hyperactivity, convulsions.</li><li>Interstitial nephritis.</li><li>Leucopenia, thrombocytopenia, haemolytic anaemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>]  </p><!-- end field 7297f544-d007-4654-97a0-a877009cbbb4 --><!-- end item 45c70add-38a7-4c30-9d49-a877009cb8dd -->","subChapters":[]},{"id":"7d67da79-c8eb-5a75-90e1-b6f5591366a6","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field fec8d0f9-8ed1-4b93-a8ba-a877009ce025 --><h3>What drug interactions are associated with co-amoxiclav?</h3><!-- end field fec8d0f9-8ed1-4b93-a8ba-a877009ce025 -->","summary":"","htmlStringContent":"<!-- begin item 7d55a961-7cc3-4f7f-8093-a877009cdd99 --><!-- begin field f0b8e220-1997-4efb-ab04-a877009ce025 --><ul><li><strong>Allopurinol </strong>— concomitant use of allopurinol and amoxicillin may increase the incidence of skin rashes.</li><li><strong>Methotrexate </strong>— co-amoxiclav may reduce methotrexate clearance, causing an increased risk of toxicity.<ul><li>Monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected.</li></ul></li><li><strong>Mycophenolate mofitil</strong> — reduction in the level of active metabolite may occur when given with co-amoxiclav.</li><li><strong>Oral anticoagulants (warfarin, phenindione) </strong>— prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.<ul><li>Monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of a penicillin. Adjustment of the anticoagulant dose may be necessary.</li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of co-amoxiclav.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Probenecid </strong>— concomitant administration may result in increased levels of amoxicillin, but not clavulanic acid.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">FSRH, 2017</a>]</p><!-- end field f0b8e220-1997-4efb-ab04-a877009ce025 --><!-- end item 7d55a961-7cc3-4f7f-8093-a877009cdd99 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}